Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT ID: NCT03686124 Phase: PHASE1 / PHASE2 Sponsor: Immatics US, Inc. Status: Recruiting

SUMMARY

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

KEY ELIGIBILITY CRITERIA

- * Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- * HLA-A*02:01 positive
- * For patients with ovarian/fallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
- * For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma.
- * Measurable disease according to RECIST 1.1
- * Adequate selected organ function per protocol
- * Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.
- * Life expectancy more than 5 months
- * Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8

ENROLLMENT CONTACT

Allison Warner, MD

Stanford Cancer Institute

Stanford, California, United States

Email: allison.betof@stanford.edu

Total sites: 21 | 21 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT03686124) and public sources. Generated by FindMyCure.ai.